MiNK Therapeutics Q4 EPS $(0.16) Misses $(0.15) Estimate
Portfolio Pulse from dijoy@benzinga.com
MiNK Therapeutics (NASDAQ:INKT) reported a Q4 EPS loss of $(0.16), missing the consensus estimate of $(0.15) by 6.67%. However, this represents a 30.43% improvement over the $(0.23) per share loss from the same period last year.
March 21, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MiNK Therapeutics reported a Q4 EPS loss of $(0.16), missing estimates but showing year-over-year improvement.
While MiNK Therapeutics missed the consensus estimate, the improvement from the previous year's loss indicates progress in the company's financial health. This mixed result could lead to neutral short-term market reaction as investors weigh the missed expectations against the year-over-year improvement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100